Dear Editor, I would like to comment on the article "COVID-19 should be a methylene blue "promoter"[11 Evora PRB. COVID-19 should be a methylene blue "promoter". Braz J Cardiovasc Surg. 2020;35(4):604-5. doi:10.21470/1678-9741-1-2020-0607.
https://doi.org/10.21470/1678-9741-1-202...
]". Evora noted that "I decided to resubmit the letter now, considering that COVID-19 should be a methylene blue 'promoter', and the dye can get the lifesaving status it deserves [11 Evora PRB. COVID-19 should be a methylene blue "promoter". Braz J Cardiovasc Surg. 2020;35(4):604-5. doi:10.21470/1678-9741-1-2020-0607.
https://doi.org/10.21470/1678-9741-1-202...
]." In fact, the use of classic available agent as a possible therapeutic agent for the emerging COVID-19 should be supported. It is better than do nothing. Many classic drugs such as hydroxychloroquine are proposed and tested for managing COVID-19[22 Joob B, Wiwanitkit V. Evidence of protective effect of hydroxychloroquine on COVID-19. J Rheumatol. 2020;47(10):1587. doi:10.3899/jrheum.200638.
https://doi.org/10.3899/jrheum.200638...
]. At the moment, we have to take the risk of a new alternative proposal for the treatment of COVID-19 such as convalescent plasma therapy[33 Wiwanitkit V. Convalescent plasma therapy in the treatment of COVID-19: some considerations: correspondence. Int J Surg. 2020;80:26. doi:10.1016/j.ijsu.2020.06.029.
https://doi.org/10.1016/j.ijsu.2020.06.0...
]. Using a safe and well-known agent might not have a confirmation for its efficacy but we have many data on its safety, and it might be a good alternative option compared to a totally unknown new alternative.
REFERENCES
-
1Evora PRB. COVID-19 should be a methylene blue "promoter". Braz J Cardiovasc Surg. 2020;35(4):604-5. doi:10.21470/1678-9741-1-2020-0607.
» https://doi.org/10.21470/1678-9741-1-2020-0607 -
2Joob B, Wiwanitkit V. Evidence of protective effect of hydroxychloroquine on COVID-19. J Rheumatol. 2020;47(10):1587. doi:10.3899/jrheum.200638.
» https://doi.org/10.3899/jrheum.200638 -
3Wiwanitkit V. Convalescent plasma therapy in the treatment of COVID-19: some considerations: correspondence. Int J Surg. 2020;80:26. doi:10.1016/j.ijsu.2020.06.029.
» https://doi.org/10.1016/j.ijsu.2020.06.029
Publication Dates
-
Publication in this collection
22 Feb 2021 -
Date of issue
Jan-Feb 2021